ACTIVE_NOT_RECRUITING

Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This will be a multicenter, prospective, open label, non-randomized, single arm 12 month study, evaluating the safety and effectiveness of the TECHNOLAS TENEO 317 Model 2 (Software version "1.28 US") excimer laser when used in LASIK surgery to treat hyperopia with or without hyperopic astigmatism. Both eyes of a subject may be enrolled so long as both eyes meet all inclusion/exclusion requirements. Analysis of the primary effectiveness endpoint will be completed at refractive stability.

Official Title

A Study to Investigate the Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism

Quick Facts

Study Start:2022-11-15

Study Completion:2026-11-20

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:ACTIVE_NOT_RECRUITING

Study ID

NCT05264623

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:22 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Subjects 22 years of age or older at the time of the pre-operative examination. 2. Manifest, distance corrected visual acuity (CDVA) 20/25 (logMAR 0.10) or better in an operative eye 3. Pre-operative refractive error of hyperopia with spherical component of 0.00 D to +4.00 D with or without cylinder up to +2.00 D, with MRSE of ≥ 0.375 D and ≤ +5.00 D based on the manifest refraction in thestudy eye(s). This would exclude eyes with cylinder-only corrections \< +0.75D and sphere-only corrections \< +0.375D) 4. Difficulty maintaining uncorrected distance visual acuity (UDVA) of 20/40 or better, as evidenced by need for constant contact lens or spectacle wear. 5. Difference between manifest refractive and cycloplegic spherical equivalent ≤ 0.75 D, difference between manifest and cycloplegic cylinder ≤ ± 0.50 D and difference between manifest and cycloplegic cylinder axis ≤ ± 15 degrees. 6. Stable refraction (i.e., a change of ≤ ± 0.50 D in MRSE) for a minimum of 12 months prior to surgery, as verified by consecutive refractions, medical records, or prescription history. 7. Agree to discontinue use of contact lenses for at least 2 weeks (for rigid or toric lenses) or 3 days (for soft contact lenses) prior to the first refraction used to establish stability and through the day of surgery. 8. All contact lens wearers must demonstrate a stable refraction in an eye to be treated, as follows: two consecutive examinations at least 1 week apart within ± 0.50 D manifest refractive spherical equivalent and within ± 15 degrees cylinder axis. 9. Agree to emmetropia correction for each treated eye. 10. Anticipated postoperative stromal bed thickness of at least 250 microns. 11. Can lie flat without difficulty. 12. Willing and able to read, understand, and sign a written informed consent form (ICF). 13. Willing and able to comply with the schedule for all post-surgery follow-up visits.	1. Acute or chronic disease or illness that would increase operative risk or confound the results of the study (e.g., dry eye disease, cataract, glaucoma, immuno-compromised, rheumatoid arthritis, clinically significant atopic disease, acne rosacea, autoimmune disease, endocrine disorders, lupus, systemic connective tissue disease, diabetes, or severe atopic disease). 2. Use of medications by any administration route that may increase risk to the subject or may confound the outcome of the study, including those known to affect wound healing (e.g., systemic corticosteroids, antimetabolites). 3. Ocular conditions, other than hyperopia with or without astigmatism that may predispose the subject to future complications including but not limited to: 1. Evidence or history of retinal vascular disease 2. Evidence or history of active or inactive corneal disease or infection (e.g., recurrent corneal erosion syndrome, herpes simplex or herpes zoster keratitis) in either eye. 3. Evidence or history of glaucoma or glaucoma suspect (IOP \> 24mmHg) by exam findings and/or family history 4. Previous intraocular or corneal surgery in an eye considered for eligibility that might confound the outcome of the study or increase the risk to the subject. 5. An increased risk for developing strabismus post-treatment or an ocular muscle disorder (e.g., strabismus or nystagmus) affecting fixation. 6. Known sensitivity to any study medications (e.g., used during LASIK procedure and postoperative care). 7. Have central corneal scars affecting visual acuity. 8. Have mixed astigmatism. 9. Presence of keratoconus, keratoconus suspect, subclinical or forme fruste keratoconus, corneal dystrophy, or other corneal irregularity (e.g., irregular astigmatism) or abnormal corneal topography 10. Presence of visually significant or progressive cataract in an eye considered for eligibility. 11. Actively taking medications contraindicated with LASIK such as isotretinoin (Accutane) or amiodarone hydrochloride (Cordarone). 12. Have a cardiac pacemaker, implanted defibrillator, or other implanted electronic device. 13. Pregnant, lactating, or subjects who plan to become pregnant during the course of the study. 14. Are participating in any other trial within 30 days of screening or during this clinical trial. 15. Eyes with mesopic pupil size \> 7.0 mm. 16. Have a Schirmer's pre-operative test without anesthesia \< 4 mm after 5 minutes

Inclusion Criteria

Exclusion Criteria

1. Subjects 22 years of age or older at the time of the pre-operative examination.
2. Manifest, distance corrected visual acuity (CDVA) 20/25 (logMAR 0.10) or better in an operative eye
3. Pre-operative refractive error of hyperopia with spherical component of 0.00 D to +4.00 D with or without cylinder up to +2.00 D, with MRSE of ≥ 0.375 D and ≤ +5.00 D based on the manifest refraction in thestudy eye(s). This would exclude eyes with cylinder-only corrections \< +0.75D and sphere-only corrections \< +0.375D)
4. Difficulty maintaining uncorrected distance visual acuity (UDVA) of 20/40 or better, as evidenced by need for constant contact lens or spectacle wear.
5. Difference between manifest refractive and cycloplegic spherical equivalent ≤ 0.75 D, difference between manifest and cycloplegic cylinder ≤ ± 0.50 D and difference between manifest and cycloplegic cylinder axis ≤ ± 15 degrees.
6. Stable refraction (i.e., a change of ≤ ± 0.50 D in MRSE) for a minimum of 12 months prior to surgery, as verified by consecutive refractions, medical records, or prescription history.
7. Agree to discontinue use of contact lenses for at least 2 weeks (for rigid or toric lenses) or 3 days (for soft contact lenses) prior to the first refraction used to establish stability and through the day of surgery.
8. All contact lens wearers must demonstrate a stable refraction in an eye to be treated, as follows: two consecutive examinations at least 1 week apart within ± 0.50 D manifest refractive spherical equivalent and within ± 15 degrees cylinder axis.
9. Agree to emmetropia correction for each treated eye.
10. Anticipated postoperative stromal bed thickness of at least 250 microns.
11. Can lie flat without difficulty.
12. Willing and able to read, understand, and sign a written informed consent form (ICF).
13. Willing and able to comply with the schedule for all post-surgery follow-up visits.

1. Acute or chronic disease or illness that would increase operative risk or confound the results of the study (e.g., dry eye disease, cataract, glaucoma, immuno-compromised, rheumatoid arthritis, clinically significant atopic disease, acne rosacea, autoimmune disease, endocrine disorders, lupus, systemic connective tissue disease, diabetes, or severe atopic disease).
2. Use of medications by any administration route that may increase risk to the subject or may confound the outcome of the study, including those known to affect wound healing (e.g., systemic corticosteroids, antimetabolites).
3. Ocular conditions, other than hyperopia with or without astigmatism that may predispose the subject to future complications including but not limited to:
1. Evidence or history of retinal vascular disease
2. Evidence or history of active or inactive corneal disease or infection (e.g., recurrent corneal erosion syndrome, herpes simplex or herpes zoster keratitis) in either eye.
3. Evidence or history of glaucoma or glaucoma suspect (IOP \> 24mmHg) by exam findings and/or family history
4. Previous intraocular or corneal surgery in an eye considered for eligibility that might confound the outcome of the study or increase the risk to the subject.
5. An increased risk for developing strabismus post-treatment or an ocular muscle disorder (e.g., strabismus or nystagmus) affecting fixation.
6. Known sensitivity to any study medications (e.g., used during LASIK procedure and postoperative care).
7. Have central corneal scars affecting visual acuity.
8. Have mixed astigmatism.
9. Presence of keratoconus, keratoconus suspect, subclinical or forme fruste keratoconus, corneal dystrophy, or other corneal irregularity (e.g., irregular astigmatism) or abnormal corneal topography
10. Presence of visually significant or progressive cataract in an eye considered for eligibility.
11. Actively taking medications contraindicated with LASIK such as isotretinoin (Accutane) or amiodarone hydrochloride (Cordarone).
12. Have a cardiac pacemaker, implanted defibrillator, or other implanted electronic device.
13. Pregnant, lactating, or subjects who plan to become pregnant during the course of the study.
14. Are participating in any other trial within 30 days of screening or during this clinical trial.
15. Eyes with mesopic pupil size \> 7.0 mm.
16. Have a Schirmer's pre-operative test without anesthesia \< 4 mm after 5 minutes

Contacts and Locations

Principal Investigator

Rosangela Nolasco

STUDY_DIRECTOR

Bausch & Lomb Incorporated

Study Locations (Sites)

Site 113

Newport Beach, California, 92660

United States

Site 111

Fort Myers, Florida, 33912

United States

Site 101

Bloomington, Minnesota, 55420

United States

Site 104

Saint Louis Park, Minnesota, 55416

United States

Site 103

Omaha, Nebraska, 68118

United States

Site 102

Amherst, New York, 14228

United States

Site 112

Pittsburgh, Pennsylvania, 15213

United States

Site 108

Sioux Falls, South Dakota, 57108

United States

Site 106

Cedar Park, Texas, 78613

United States

Collaborators and Investigators

Sponsor: Bausch & Lomb Incorporated

Rosangela Nolasco, STUDY_DIRECTOR, Bausch & Lomb Incorporated

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-11-15

Study Completion Date2026-11-20

Study Record Updates

Study Start Date2022-11-15

Study Completion Date2026-11-20

Terms related to this study

Additional Relevant MeSH Terms

Hyperopia